Biotech catalysts

Public drugmakers ranked by their active Phase 3 clinical pipeline, from ClinicalTrials.gov, alongside recent FDA drug recalls from openFDA. A large or growing late-stage pipeline is a forward catalyst; a recent Class I/II recall is a risk flag. 4 of these are also names the PriorMoves 13F model ranks. As of 2026-08-31.

Descriptive context, not a recommendation and not a return claim.

#	Company	Active Phase 3	Recent recalls	Worst class	On model board
1	MRK Merck	138	-	-	○
2	LLY Eli Lilly	104	-	-	○
3	JNJ Johnson & Johnson	98	-	-	○
4	PFE Pfizer	92	-	-	○
5	ABBV AbbVie	78	1	Class III	○
6	BMY Bristol Myers Squibb	77	-	-	○
7	AMGN Amgen	56	5	Class II	● 80
8	REGN Regeneron	51	-	-	● 71
9	GILD Gilead Sciences	42	-	-	○
10	BIIB Biogen	19	-	-	○
11	ALNY Alnylam	0	-	-	○
12	AZN AstraZeneca	0	-	-	○
13	BAX Baxter	0	2	Class II	○
14	BMRN BioMarin	0	-	-	○
15	BNTX BioNTech	0	-	-	● 75
16	EXEL Exelixis	0	-	-	○
17	GSK GSK	0	-	-	○
18	HIK Hikma	0	1	Class II	○
19	INCY Incyte	0	-	-	○
20	JAZZ Jazz	0	-	-	○
21	MRNA Moderna	0	-	-	○
22	NVAX Novavax	0	-	-	○
23	NVS Novartis	0	2	Class II	○
24	SNY Sanofi	0	-	-	○
25	SRPT Sarepta	0	-	-	● 73
26	TEVA Teva	0	14	Class II	○
27	VRTX Vertex	0	-	-	○
28	VTRS Viatris	0	3	Class II	○